Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recipients of matched related, matched unrelated, or mismatched stem cell transplantation~* At least 180 days since allogeneic stem cell transplantation procedure~* Patients must have steroid-refractory chronic GVHD, defined as having persistent signs and symptoms despite the use of prednisone~* Stable dose of corticosteroids for 4 weeks prior to enrollment~* Adequate bone marrow function: absolute neutrophil count (ANC) \> 500/mm; platelets \> 20,000 ul~* Adequate renal function: creatinine \< 3.0 mg/dl~* Adequate hepatic function: bilirubin \< 3.0 mg/dl; AST \< 90 IU~Exclusion Criteria:~* Prednisone requirement greater than 2 mg/kg/day or equivalent~* Known life-threatening sensitivity to rituximab or other anti-B cell antibody.~* Prior exposure to any new immunosuppressive medication in the preceding 4 weeks prior to enrollment.~* Active, uncontrolled infection~* Evidence of natural exposure to hepatitis B or C.~* Active malignant disease relapse~* Donor lymphocyte infusion within the preceding 100 days.~* Life expectancy of less than 3 months.~* Pregnancy or lactation~* Evidence of HIV seropositivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).